Interaction Checker
Potential Interaction
Dolutegravir/Lamivudine (DTG/3TC)
Phenytoin
Quality of Evidence: Very Low
Summary:
Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Dolutegravir is mainly metabolized by UGT1A1 and to a lesser extent by CYP3A4. Lamivudine is eliminated renally. Dolutegravir is unlikely to affect phenytoin metabolism. No interaction is expected with lamivudine. However, dolutegravir exposure is expected to decrease due to induction of UGT1A1 and CYP3A by phenytoin. The American product label for Dovato advises to avoid coadministration due to insufficient data to make dosing recommendations. However, the European product label for Dovato recommends that an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato (dolutegravir/lamivudine), should be taken. This dose adjustment should be maintained for approximately 2 weeks after stopping phenytoin as the inducing effect may persist after discontinuation of a strong inducer. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended. No significant interaction is expected with lamivudine.
Description:
View all available interactions with Dolutegravir/Lamivudine (DTG/3TC) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.